Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc.

RNACNYSE / NASDAQHealthcareSmall cap

$6.14+$0.25 (+4.2%)

Last close · Data as of Nov 20, 2026

Market cap
$192.4M
P/E
-1.5x
EV / EBITDA
-1.0x
Revenue
$2.8M
Net margin
-4658.6%
ROCE
-30.8%

-14.1% over the last year

Cartesian Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-4.0%
3M
-40.0%
6M
-5.8%
1Y
-14.1%
5Y
-93.6%

52-week range

Day change +$0.25 (+4.2%) from $5.89 to $6.14 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in RNAC, bought on each weekday since 2021.

News & filings

What Cartesian Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths (1)

  • Current assets are 8.65 times current liabilities.
  • The stored ratios (as of 11 Jun 2026) describe a profitable period while fiscal 2025 shows a net loss: the two cover different periods, so the ratio points are not shown.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases.

Read moreShow less

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

Sector
Healthcare
Shares outstanding
26.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$192.4M
P/E
-1.5x
P/B
-1.5x
EV / EBITDA
-1.0x
EV / Sales
28.6x
P/S
68.8x
52-week high
$10.59
52-week low
$5.84

Profitability

Operating margin
-3099.9%
Net margin
-4658.6%
EBITDA margin
-2994.1%
ROE
103.2%
ROCE
-30.8%
ROA
-44.0%
Asset turnover
0.01

Growth

Revenue
$2.8M
Revenue growth, 1Y
-92.8%
Revenue CAGR, 3Y
-70.7%
Net profit growth, 1Y
68.3%
Free cash flow
-$79.4M

Solvency

Current ratio
8.65
Debt / Equity
-0.10
Debt / Assets
0.04
CFO / Net profit
0.57
Cash / Market cap
65.0%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$2.8M
Gross profit$2.8M
Operating expenses$89.5M
Research and development$58.0M
Selling, general and administrative$31.5M
Operating income-$86.7M
Interest and other-$52.8M
Pretax income-$139.5M
Tax and other-$9.2M
Net income-$130.3M

Revenue and net profit

Revenue fell 92.8% in FY2025; net profit is the dashed line.

Cartesian Therapeutics, Inc. revenue and net profit by fiscal year
Cartesian Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$110.8M$35.4M
FY2023$26.0M-$219.7M
FY2024$38.9M-$77.4M
FY2025$2.8M-$130.3M

Cash flows

FY2025: -$73.9M from operations, -$79.4M free after investment (dashed).

Cartesian Therapeutics, Inc. operating and free cash flow by fiscal year
Cartesian Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$31.6M-$32.8M
FY2023-$51.2M-$51.4M
FY2024-$23.7M-$32.8M
FY2025-$73.9M-$79.4M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$2.8M-92.8%1Y
EBITDA
-$83.7M
Net profit
-$130.3M
Cash from operations
-$73.9M
Free cash flow
-$79.4M
Revenue CAGR, 3Y
-70.7%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$2.8M-$83.7M-$130.3M-$79.4M103.2%-92.8%+68.3%

Monthly returns

Month-by-month returns of RNAC across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$296.4M
Liabilities$422.6M
Equity-$126.2M
Paid-in capital$700.7M
Retained earnings-$822.4M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; RNAC highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. Cartesian Therapeutics, Inc. (this company)28.6x

Not shown (no positive earnings and no EV / Sales): Nkarta, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Cartesian Therapeutics, Inc.RNACthis company$192.4M-1.5x-1.5x103.2%-1.0x
Alector, Inc.ALEC$201.0M—6.6x-466.3%—
Nkarta, Inc.NKTX$198.2M—0.6x-33.3%—
Anika Therapeutics, Inc.ANIK$196.8M-18.1x1.4x-7.6%-31.1x
Lucid Diagnostics Inc.LUCD$194.6M—17.8x-645.1%—
KORU Medical Systems, Inc.KRMD$190.2M-72.1x11.2x-15.5%-85.5x
Tonix Pharmaceuticals Holding Corp.TNXP$189.4M-1.5x0.8x-50.6%0.1x
MediWound Ltd.MDWD$185.7M-7.8x4.3x-54.7%-8.8x
Stereotaxis, Inc.STXS$183.7M-8.5x13.6x-160.5%-8.5x
Peer median—-8.5x5.4x-52.7%-8.8x

Year-to-date ROI

RNAC since 1 January, against earlier years.

Historical volatility

RNAC's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Cartesian Therapeutics, Inc. operating margin by fiscal year
Cartesian Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY202213.1%
FY2023-329.7%
FY2024-93.3%
FY2025-3096.4%
LineFY2025
Operating expensesOperating Expense$89.5M
Research and developmentResearch And Development$58.0M
Total expensesTotal Expenses$89.5M
Pretax incomePretax Income-$139.5M

Learn while you research

Academy chapters picked for Cartesian Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →